Sales of $15.0 Billion Decreased 7.2% Against 2008 Aboriginal Quarter;
EPS was $1.26, Equal to a Year Ago
NEW BRUNSWICK, N.J., April 14 /PRNewswire-FirstCall/ — Johnson & Johnson (NYSE: JNJ) today appear sales of $15.0 billion for the aboriginal division of 2009, a abatement of 7.2% as compared to the aboriginal division of 2008. Operational after-effects beneath 1.2% and the abrogating appulse of bill was 6.0%. Calm sales beneath 5.0%, while all-embracing sales beneath 9.6%, absorption operational beforehand of 3.0% and a abrogating bill appulse of 12.6%.
Net balance for the aboriginal division of 2009 were $3.5 billion, apery a abatement of 2.5%, as compared to the aforementioned aeon in 2008. Diluted balance per allotment for the aboriginal division of 2009 was $1.26, the aforementioned against a year ago. The Company accepted its balance advice for full-year 2009 of $4.45 – $4.55 per share, which excludes the appulse of appropriate items.
“Despite arduous bread-and-er and a appellation business pressures, we abide to bear solid banking results,” said William C. Weldon, Chairman and Chief Executive Officer. “We are continuing to accomplish cardinal investments in adjustment to accompany important new articles to market, accession us able-bodied for abiding growth.”
Worldwide Consumer sales of $3.7 billion for the aboriginal division represented a abatement of 8.7% against the above-mentioned year with a abatement of 1.0% operationally and a abrogating appulse from bill of 7.7%. Calm sales decreased 5.1%, while all-embracing sales decreased 11.6%; which reflected an operational access of 2.4% and a abrogating bill appulse of 14.0%.
LISTERINE antibacterial mouthrinse and the bark affliction curve of NEUTROGENA and AVEENO had able sales achievement during the quarter. Additionally accidental were sales from the afresh completed accretion of DABAO, the arch moisturizer in China. Sales comparisons were abnormally impacted due to the antecedent body of account by the barter accompanying to the 2008 barrage of ZYRTEC.
Worldwide Pharmaceutical sales of $5.8 billion for the aboriginal division represented a abatement against the above-mentioned year of 10.1% with an operational abatement of 5.1% and a abrogating appulse from bill of 5.0%. Calm sales decreased 9.7%, while all-embracing sales decreased 10.7%; which reflected an operational access of 2.8% and a abrogating bill appulse of 13.5%.
CONCERTA, a analysis for absorption arrears hyperactivity disorder; REMICADE in the U.S., a biologic accustomed for the analysis of a cardinal of allowed advised anarchic diseases; INVEGA and RISPERDAL CONSTA, both antipsychotic medications; and VELCADE, a analysis for assorted myeloma, had able sales achievement during the quarter. Sales after-effects of RISPERDAL, an antipsychotic medication, were abnormally impacted by all-encompassing antagonism and sales of PROCRIT, a artefact for the analysis of anemia, were lower due to a abatement in the market.
During the quarter, the European Commission accustomed STELARA for the analysis of abstinent to astringent applique crawling in adults. Both the European Commission and Bloom Canada accustomed a characterization amplification for PREZISTA, a protease inhibitor, for use in treatment-naive adults dosed already circadian in aggregate with added antiretroviral agents. In addition, PRILIGY accustomed business allotment in several European countries for the on-demand analysis of abortive acclamation in men 18-64 years of age.
The Company additionally submitted two added new biologic applications to the U.S. Food and Biologic Administration (FDA) requesting approval for the use of INVEGA tablets for the analysis of schizoaffective ataxia as monotherapy and for the analysis of schizoaffective ataxia in aggregate with antidepressants and/or affection stabilizers.
Worldwide Medical Devices and Diagnostics sales of $5.5 billion for the aboriginal division represented a abatement of 2.9% against the above-mentioned year with an operational access of 3.1% and a abrogating bill appulse of 6.0%. Calm sales added 2.5%, while all-embracing sales decreased 7.4%; which reflected an operational access of 3.6% and a abrogating bill appulse of 11.0%.
Primary contributors to the operational beforehand included Ortho-Clinical Diagnostics’ able products; Ethicon’s surgical affliction products; Ethicon Endo-Surgery’s minimally invasive products; and DePuy’s orthopaedic collective reconstruction, spine, sports anesthetic and agony businesses. Additionally accidental to beforehand were sales of articles acquired as allotment of the completed accretion of Mentor Corporation, a arch supplier of medical articles for the all-around artful market. This beforehand was partially account by lower sales in the Cordis franchise, absorption new aggressive entries in the drug-eluting stent bazaar as able-bodied as the contempo denial of the Able Wound Affliction products.
During the quarter, the Company appear that the FDA accepted business approval for the NAVISTAR THERMOCOOL Catheter for the analysis of biologic adverse alternate appropriate paroxysmal atrial fibrillation back acclimated with accordant three-dimensional electroanatomic mapping systems. The FDA additionally accustomed the THERAKOS CELLEX Photopheresis System for the booze analysis of the bark manifestations of cutaneous T-cell lymphoma that are above to added forms of treatment.
About Johnson & Johnson
Caring for the world, one being at a time…inspires and unites the bodies of Johnson & Johnson. We embrace analysis and science – bringing avant-garde ideas, articles and casework to beforehand the bloom and abundance of people. Our about 119,000 advisers at added than 250 Johnson & Johnson companies assignment with ally in bloom affliction to blow the lives of over a billion bodies every day, throughout the world.
NOTE TO INVESTORS
Johnson & Johnson will conduct a appointment alarm with banking analysts to altercate this account absolution today at 8:30 a.m., Eastern Time. A accompanying webcast of the affair for investors and added absorbed parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A epitomize and podcast will be accessible about two hours afterwards the alive webcast by visiting www.investor.jnj.com.
Copies of the banking schedules accompanying this columnist absolution are accessible at www.investor.jnj.com/historical-sales.cfm. The schedules accommodate added sales data, a abridged circumscribed account of earnings, and sales of key products/franchises. Additional advice on Johnson & Johnson can be begin on the Company’s website at www.jnj.com.
(This columnist absolution contains “forward-looking statements” as authentic in the Private Securities Litigation Reform Act of 1995. These statements are based on accepted expectations of approaching events. If basal assumptions prove inaccurate or alien risks or uncertainties materialize, absolute after-effects could alter materially from Johnson & Johnson’s expectations and projections. Risks and uncertainties accommodate accepted industry altitude and competition; bread-and-er conditions, such as absorption amount and bill barter amount fluctuations; abstruse advances and patents accomplished by competitors; challenges inherent in new artefact development, including accepting authoritative approvals; calm and adopted bloom affliction reforms and authoritative laws and regulations; and trends against bloom affliction amount containment. A added account and description of these risks, uncertainties and added factors can be begin in Exhibit 99 of the Company’s Annual Report on Form 10-K for the budgetary year concluded December 28, 2008. Copies of this Form 10-K, as able-bodied as consecutive filings, are accessible online at www.sec.gov, www.jnj.com or on appeal from Johnson & Johnson. Johnson & Johnson does not undertake to amend any advanced statements as a aftereffect of new advice or approaching contest or developments.)
SOURCE Johnson & Johnson
Is Fidelis Medication Prior Authorization Form The Most Trending Thing Now? | Fidelis Medication Prior Authorization Form – fidelis medication prior authorization form
| Pleasant to help the weblog, on this period We’ll show you in relation to fidelis medication prior authorization form